衞寧健康(300253.SZ):終止換股吸收合併創業慧康事項 7月26日起復牌
格隆匯7月23日丨衞寧健康(300253.SZ)公佈,此前披露,公司與創業慧康科技股份有限公司(“創業慧康”)籌劃由公司向創業慧康全體股東發行A股股票的方式換股合併創業慧康,併發行A股股票募集配套資金事宜,公司證券自2021年7月19日(星期一)開市起停牌。
經認真研究相關各方意見,為切實維護雙方及廣大投資者利益,雙方經審慎研究協商一致決定終止籌劃該次重大資產重組事項。
經公司向深圳證券交易申請,公司證券(證券簡稱:衞寧健康,證券代碼:300253,債券簡稱:衞寧轉債,債券代碼:123104)自2021年7月26日(星期一)開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.